Helios Hospital Berlin-Buch

FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC

Abstract Introduction: FGFR alterations occur in approximately 2% of non-small cell lung cancer (NSCLC) patients, predominantly in squamous cell histology (sqNSCLC). We evaluated the efficacy of the selective FGFR1-4 inhibitor erdafitinib in patients with FGFR-altered NSCLC. Meth...

Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario

Abstract Tagraxofusp (TAG), a CD123-directed protein-drug conjugate, is approved in front-line and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). Multicenter real-world outcomes and the contribution of up-front consolidation post-TAG remain less defined...

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

Abstract Background Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of the combination of venetoclax (VEN) with azacitidine (AZA) or decitabine (DAC) in the European Union in 2021 for the treatment of patients wit...